Overview

First in Man Study of Safety, Tolerability and PK Profile of RBP-7000

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability and PK profile of a single dose of 60mg RBO-7000 in stable subjects with schizophrenia who are on medication other than risperidone.
Phase:
Phase 1
Details
Lead Sponsor:
Indivior Inc.